Prenetics Global (NASDAQ: PRE) has provided financial guidance for its third quarter, projecting sales to fall within the range of $63.000 million to $64.000 million. This forecast represents a beat against the consensus analyst estimate of $59.310 million, indicating potential upside in top-line performance.

The company’s guidance suggests that actual revenues could exceed market expectations by as much as $4.690 million, or approximately 7.9%, if the upper end of the projected range is achieved. The lower bound of the guidance still surpasses the consensus estimate by $3.690 million, or roughly 6.2%.

What the Numbers Show

The divergence between the guided range and the analyst consensus highlights a positive variance in revenue expectations. With no other financial metrics disclosed in the source, the primary analytical signal is the consistent upside across the entire guided interval relative to the $59.310 million benchmark.

Prenetics Global Limited (NASDAQ: PRE) reported a mixed set of results for the second quarter of fiscal year 2026, with earnings per share beating analyst expectations while total revenue fell short of consensus estimates.

The company recorded a loss per share of $(0.53), which beat the analyst consensus estimate of $(0.71) by 25.35 percent. This represents a significant improvement over the loss of $(0.82) per share reported in the same period last year, marking a 35.37 percent reduction in losses year-on-year.

However, top-line growth did not meet market expectations. Prenetics reported quarterly sales of $46.488 million, missing the analyst consensus estimate of $48.920 million by 4.97 percent. Despite the miss against estimates, this figure represents a robust 162.94 percent increase over sales of $17.680 million in the same period last year.

Financial Performance and Guidance

The previous reporting highlighted a consolidated revenue of $46.5 million, driven primarily by the IM8 brand. The new data refines this figure to $46.488 million. The IM8 brand, co-founded with David Beckham, remains the primary growth engine, having generated $45.0 million in revenue for the quarter in prior disclosures, marking a 359% year-on-year surge.

Management had previously highlighted July 2026 as the strongest month in the company’s history, with IM8 recording $20.9 million in monthly revenue. Building on this momentum, Prenetics raised its full-year FY26 guidance for IM8 revenue to $220-230 million and initiated guidance for fiscal year 2027, projecting IM8 revenue of $400 million or more.

What the Numbers Show

The divergence between earnings performance and revenue expectations highlights the operational leverage achieved by the company. While revenue missed the specific consensus target of $48.920 million, the actual figure of $46.488 million still represents a massive 162.94% expansion from the prior year’s $17.680 million. More notably, the improvement in EPS from $(0.82) to $(0.53) suggests that cost structures are scaling more efficiently than revenue, allowing the company to reduce its loss burden significantly even as it navigates slight shortfalls against high market expectations.

Cash Flow and Strategic Shifts

A key operational milestone was achieved in July 2026, when the company recorded its first month of positive consolidated Adjusted Free Cash Flow. Management expects this metric to remain positive for the third quarter and beyond. The financial results reflect a strategic repositioning under IFRS 5, with discontinued operations presented separately following the divestiture of non-core businesses such as ACT Genomics, Europa, and Insighta.